Plus therapeutics reports stockholders' equity in excess of $2.5 million in compliance with nasdaq equity requirements

Houston, aug. 15, 2025 (globe newswire) --  plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied nasdaq listing rule 5550(b)(1) (the “equity rule”), as of june 30, 2025. the equity rule requires listed companies to maintain a minimum of $2.5 million in stockholders' equity.
PSTV Ratings Summary
PSTV Quant Ranking